Libya vs Montserrat: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Libya
0.2%
in 2024
Montserrat
0.2%
in 2024
Libya rank
78th
Montserrat rank
78th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Libya
- Montserrat
How they compare
Libya currently reports 0.2% against 0.2% in Montserrat, a difference of 0.0%.
Across all 10 years both countries report, Montserrat has been ahead every year.
Libya ranks 78th and Montserrat ranks 78th of 215 countries.
Montserrat has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Libya | Montserrat | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.3% | 0.1% | Montserrat |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Libya or Montserrat?
- Libya, at 0.2% against 0.2% in Montserrat as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Libya and Montserrat?
- 0.0%, with Libya ahead.
- How many years of comparable data are there for Libya and Montserrat?
- 10 years are reported by both, from 2015 to 2024.
- How do Libya and Montserrat rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Libya ranks 78th and Montserrat ranks 78th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.